We use press releases to update external stakeholders on our progress. We want to make sure you have all the information you need to provide comprehensive feedback on our reports.
Subscribers can expect to receive press releases at the following milestones: Topic Announcement, Draft Evidence Report, Revised Evidence Report, and Final Evidence Report.
You can also find the week’s press releases in our newsletter.
For any questions, please contact mediainquiries@icer.org.
Sign up for our Press Releases and Newsletter!
Featured Press Releases
In Revised Evidence Report, ICER Confirms Judgment That Evidence is Insufficient to Demonstrate Net Health Benefit of Aducanumab for Patients with Alzheimer’s Disease
Accepting the uncertainty associated with the positive estimate obtained from pooled data from both pivotal trials, the revised report finds the price range needed to reach standard cost-effectiveness thresholds is $3,000-$8,400, representing an 85%-95% discount from the announced list price.
06/30/2021ICER Launches Early Insights Webinar Series on Draft ICER Reports and Real World ICER Analytics Case Studies for Payers and Life Science Organizations
First webinar to cover evidence report for Alzheimer’s disease.
06/24/2021ICER Analytics™ Launched to Accelerate the Real-World Application of ICER Reports, Helping Payers, the Life Science Industry, and Health Care Policy Makers Move From Insight to Action
ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices.
11/30/2020